v3.26.3
Summary of Significant Accounting Policies - Schedule of Segment Information for Revenue, Significant Operating Expenses and Other Income (Expense), and Net Loss (Details) - USD ($)
$ in Thousands
 2 Months Ended 3 Months Ended 8 Months Ended 9 Months Ended
Aug. 16, 2026
Sep. 30, 2026
Sep. 30, 2025
Aug. 16, 2026
Sep. 30, 2026
Sep. 30, 2025
Revenues:            
Total revenues, net   $ 353,171 $ 120,700   $ 791,362 $ 347,898
Cost of revenues:            
Total cost of revenues   20,450 6,563   45,435 12,855
Total segment research and development   143,506 112,874   419,590 335,536
Selling, general and administrative   200,854 137,621   551,011 373,140
Restructuring, impairment, and related charges   0 8,841   0 10,216
Total operating costs and expenses   364,810 265,899   1,016,036 731,747
Loss from operations   (11,639) (145,199)   (224,674) (383,849)
Other income (expense), net:            
Interest income   13,105 6,239   26,010 15,522
Interest expense   (13,255) (11,739)   (39,475) (41,467)
Noncash interest expense on deferred royalty obligations [1]   (42,282) (36,410)   (123,500) [2] (86,460) [2]
Net loss from equity method investments   (7,312) (15,834)   (32,030) (51,579)
Loss on extinguishment of debt   0 0   0 (21,155)
Other income, net   2,116 16,461   11,956 31,240
Total other expense, net   (47,628) (41,283)   (157,039) (153,899)
Loss before income taxes   (59,267) (186,482)   (381,713) (537,748)
Provision for (benefit from) income taxes   1,229 (1,545)   1,229 555
Net loss   (60,496) (184,937)   (382,942) (538,303)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests   3,786 2,194   9,973 6,235
Net loss attributable to BridgeBio   (56,710) (182,743)   (372,969) (532,068)
Preferred stock dividends and accretion   26,293 0   26,293 0
Net loss attributable to common stockholders of BridgeBio   (83,003) (182,743)   (399,262) (532,068)
Related Party            
Other income (expense), net:            
Noncash interest expense on deferred royalty obligations $ (2,942)   (5,383) $ (13,878)   (5,560)
Net product revenue            
Revenues:            
Total revenues, net   253,346 108,111   656,382 216,351
Cost of revenues:            
Total cost of revenues   12,317 4,028   30,577 8,910
License and services revenue            
Revenues:            
Total revenues, net   79,314 8,311   89,537 125,441
Royalty revenue            
Revenues:            
Total revenues, net   20,511 4,278   45,443 6,106
Cost of license, services, and royalty revenue            
Cost of revenues:            
Total cost of revenues   8,133 2,535   14,858 3,945
Reportable Segment            
Revenues:            
Total revenues, net   353,171 120,700   791,362 347,898
Cost of revenues:            
Total cost of revenues   20,450 6,563   45,435 12,855
Total segment research and development   143,506 112,874   419,590 335,536
Selling, general and administrative   200,854 137,621   551,011 373,140
Restructuring, impairment, and related charges   0 8,841   0 10,216
Total operating costs and expenses   364,810 265,899   1,016,036 731,747
Loss from operations   (11,639) (145,199)   (224,674) (383,849)
Other income (expense), net:            
Interest income   13,105 6,239   26,010 15,522
Interest expense   (13,255) (11,739)   (39,475) (41,467)
Noncash interest expense on deferred royalty obligations   (42,282) (36,410)   (123,500) (86,460)
Net loss from equity method investments   (7,312) (15,834)   (32,030) (51,579)
Loss on extinguishment of debt   0 0   0 (21,155)
Other income, net   2,116 16,461   11,956 31,240
Total other expense, net   (47,628) (41,283)   (157,039) (153,899)
Loss before income taxes   (59,267) (186,482)   (381,713) (537,748)
Provision for (benefit from) income taxes   1,229 (1,545)   1,229 555
Net loss   (60,496) (184,937)   (382,942) (538,303)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests   3,786 2,194   9,973 6,235
Net loss attributable to common stockholders of BridgeBio   (83,003) (182,743)   (399,262) (532,068)
Reportable Segment | Acoramidis for the treatment of ATTR-CM and primary prevention in asymptomatic carriers of a pathogenic TTR variant            
Cost of revenues:            
Total segment research and development   33,782 31,978   101,695 84,639
Reportable Segment | Infigratinib for achondroplasia and hypochondroplasia            
Cost of revenues:            
Total segment research and development   34,089 30,756   105,082 88,881
Reportable Segment | BBP-418 for LGMD2I/R9            
Cost of revenues:            
Total segment research and development   24,971 14,253   67,232 39,705
Reportable Segment | Encaleret for ADH1            
Cost of revenues:            
Total segment research and development   27,048 16,046   71,555 44,633
Reportable Segment | Other development programs            
Cost of revenues:            
Total segment research and development   3,292 357   16,815 22,323
Reportable Segment | Other research programs            
Cost of revenues:            
Total segment research and development   20,324 19,484   57,211 55,355
Reportable Segment | Net product revenue            
Revenues:            
Total revenues, net   253,346 108,111   656,382 216,351
Cost of revenues:            
Total cost of revenues   12,317 4,028   30,577 8,910
Reportable Segment | License and services revenue            
Revenues:            
Total revenues, net   79,314 8,311   89,537 125,441
Reportable Segment | Royalty revenue            
Revenues:            
Total revenues, net   20,511 4,278   45,443 6,106
Reportable Segment | Cost of license, services, and royalty revenue            
Cost of revenues:            
Total cost of revenues   $ 8,133 $ 2,535   $ 14,858 $ 3,945
[1] Including related party amounts of $(2,942) and $(13,878) for the period from July 1, 2026 to August 16, 2026 and for the period from January 1, 2026 to August 16, 2026, respectively, and $(5,383) and $(5,560) for the three and nine months ended September 30, 2025, respectively (as described in Note 9)
[2] Including related party amounts of $13,878 and $5,560 for the period from January 1, 2026 to August 16, 2026 and for the nine months ended September 30, 2025, respectively (as described in Note 9).